Drug intelligence / Profile preview

CMAB016

Development stage: Preclinical
Lead developer: Mabpharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CMAB016 is a biosimilar monoclonal antibody targeting the interleukin-4 receptor subunit alpha (IL-4Rα), currently under development by Mabpharm Ltd. It is designed to mimic the reference product, Dupixent (dupilumab), by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of type 2 inflammation. The drug is being developed for a range of inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. As of late 2024, CMAB016 is in the IND-enabling stage, with clinical trial application submission planned for 2026 and a target launch in 2029.

Other names: dupilumab biosimilar

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on CMAB016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMAB016.

Explore the full profile